The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,951.00
Ask: 1,953.00
Change: -1.00 (-0.05%)
Spread: 2.00 (0.103%)
Open: 1,942.00
High: 1,958.00
Low: 1,938.00
Prev. Close: 1,959.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Hikma in joint-venture to tap high-growth Ethiopian market

Wed, 18th Sep 2013 11:43

By Paul Sandle

LONDON, Sept 18 (Reuters) - Jordan's Hikma Pharmaceuticals has formed a joint venture with Sheikh Mohammed HusseinAl Amoudi's MIDROC Group to enter the Ethiopian healthcaremarket, where health spending is likely to more than double inthe next few years.

London-listed Hikma said the joint venture, HikmaCure, wouldcreate an Ethiopian operating company, build a localmanufacturing facility and would begin marketing anddistributing pharmaceutical products in Ethiopia.

"Ethiopia is still very underdeveloped in terms of thepharmaceutical market," Mazen Darwazah, executive vice chairmanand chief executive of Hikma's Middle East and North Africabusiness, said in an interview.

"It's a market that has huge potential for growth. We areexpecting an increase in expenditure on healthcare: today is$400 million but we are expecting it in the next couple of yearsto go up to $1 billion."

Ethiopia, Africa's second most populous nation, has seen adecade of double-digit growth, and it has leapfroggedneighbouring Kenya to become sub-Saharan Africa's fifth biggesteconomy.

The country's population of 91 million people is served byjust 5,000 doctors, compared with 40,000 doctors in Egypt for 85million people, Hikma said.

Hikma and MIDROC will provide up to $22.3 million each tothe joint venture, Hikma said.

Hikma manufactures and sells branded pharmaceuticals inMiddle Eastern and North African markets including Algeria,Saudi Arabia and Sudan. It also has a U.S. focused genericsbusiness and an injectables unit.

Jeddah-based MEDROC, which has operations in sectorsincluding petroleum, agriculture, engineering and construction,is a major investor in Ethiopia, where it has based its Africanoperations. The group's chairman, Sheikh Mohammed Al-Amoudi, isof Ethiopian-Yemeni heritage, according to his website, and heis the largest foreign investor in Ethiopia.

Analyst James Vane-Tempest at Jefferies said the jointventure was a positive for the company and it added furthercredibility to its expansion strategy.

"Ethiopia is one of the largest markets in the region and inour view offers strong long-term growth potential," he said.

Shares in the group were up 0.9 percent at 1,036 pence by1016 GMT.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.